Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease

Brain Research

Volumn 1118, Issue 1, 2006, Pages 239-250

  Iczkiewicz, Joanna ^a   Jackson, Michael J ^a   Smith, Lance A ^a   Rose, Sarah ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

MPTP treated primate; Osteopontin; Parkinson's disease; Substantia Nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; OSTEOPONTIN;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MARMOSET; MICROGLIA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION;

AGED; AGED, 80 AND OVER; ANIMALS; CALLITHRIX; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOWN-REGULATION; ENCEPHALITIS; FEMALE; GLIOSIS; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROGLIA; NEURONS; OSTEOPONTIN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; RNA, MESSENGER; SUBSTANTIA NIGRA;

CALLITHRIX JACCHUS; MARMOSETS; PRIMATES;

EID: 33751001306     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.08.036     Document Type: Article

References (64)

1. Barcia C., Sanchez B.A., Fernandez-Villalba E., Bautista V., Poza Y.P., Fernandez-Barreiro A., Hirsch E.C., and Herrero M.T. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46 (2004) 402-409
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20 (1973) 415-455
3. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., and Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 19 (1994) 151-154
4. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., and Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294 (2001) 1731-1735
5. Chao C.C., Hu S., and Peterson P.K. Glia: the not so innocent bystanders. J. Neurovirol. 2 (1996) 234-239
6. Choi J.S., Park H.J., Cha J.H., Chung J.W., Chun M.H., and Lee M.Y. Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection. J. Neuroimmunol. 141 (2003) 65-73
7. Denhardt D.T., and Guo X. Osteopontin: a protein with diverse functions. FASEB J. 7 (1993) 1475-1482
8. Denhardt D.T., Giachelli C.M., and Rittling S.R. Role of osteopontin in cellular signaling and toxicant injury. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 723-749
9. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., and Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest 107 (2001) 1055-1061
10. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., and Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 Pt 4 (1991) 1953-1975
11. Dickson D.W. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J. Neurol. 246 Suppl. 2 (1999) S006-S015
12. Ellison J.A., Velier J.J., Spera P., Jonak Z.L., Wang X., Barone F.C., and Feuerstein G.Z. Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke. Stroke 29 (1998) 1698-1706
13. Ellison J.A., Barone F.C., and Feuerstein G.Z. Matrix remodeling after stroke. De novo expression of matrix proteins and integrin receptors. Ann. N. Y. Acad. Sci. 890 (1999) 204-222
14. Fitzpatrick L.A., Severson A., Edwards W.D., and Ingram R.T. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J. Clin. Invest 94 (1994) 1597-1604
15. Gai W.P., Power J.H., Blumbergs P.C., Culvenor J.G., and Jensen P.H. Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J. Neurochem. 73 (1999) 2093-2100
16. Giachelli C.M., Bae N., Almeida M., Denhardt D.T., Alpers C.E., and Schwartz S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest 92 (1993) 1686-1696
17. Goldman J.E., Yen S.H., Chiu F.C., and Peress N.S. Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 221 (1983) 1082-1084
18. Golledge J., McCann M., Mangan S., Lam A., and Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35 (2004) 1636-1641
19. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., and Hirsch E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72 (1996) 355-363
20. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., and Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19 (1999) 3440-3447
21. Ishizawa K., and Dickson D.W. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J. Neuropathol. Exp. Neurol. 60 (2001) 647-657
22. Iczkiewicz J., Rose S., and Jenner P. Osteopontin (Eta-1) is present in the rat basal ganglia. Brain Res. Mol. Brain Res. 132 (2004) 64-72
23. Iczkiewicz J., Rose S., and Jenner P. Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. Eur. J. Neurosci. 21 (2005) 1911-1920
24. Jellinger K.A. Cell death mechanisms in neurodegeneration. J. Cell. Mol. Med. 5 (2001) 1-17
25. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 61 (2003) S4-S11
26. Jenner P., and Marsden C.D. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. J. Neural Transm., Suppl. 20 (1986) 11-39
27. Jenner P., Rupniak N.M., Rose S., Kelly E., Kilpatrick G., Lees A., and Marsden C.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 50 (1984) 85-90
28. Khan S.A., Lopez-Chua C.A., Zhang J., Fisher L.W., Sorensen E.S., and Denhardt D.T. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J. Cell. Biochem. 85 (2002) 728-736
29. Knott C., Stern G., and Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16 (2000) 724-739
30. Kuzuhara S., Mori H., Izumiyama N., Yoshimura M., and Ihara Y. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol. (Berl.) 75 (1988) 345-353
31. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46 (1999) 598-605
32. Lowe J., Blanchard A., Morrell K., Lennox G., Reynolds L., Billett M., Landon M., and Mayer R.J. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J. Pathol. 155 (1988) 9-15
33. Mayer R.J., Lowe J., Lennox G., Doherty F., and Landon M. Intermediate filaments and ubiquitin: a new thread in the understanding of chronic neurodegenerative diseases. Prog. Clin. Biol. Res. 317 (1989) 809-818
34. McGeer E.G., and McGeer P.L. The role of the immune system in neurodegenerative disorders. Mov. Disord. 12 (1997) 855-858
35. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
36. McGeer P.L., Schwab C., Parent A., and Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 54 (2003) 599-604
37. McKee M.D., and Nanci A. Secretion of osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues: a potential requirement for macrophage adhesion and phagocytosis. Anat. Rec. 245 (1996) 394-409
38. McNaught K.S., and Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297 (2001) 191-194
39. Meller R., Stevens S.L., Minami M., Cameron J.A., King S., Rosenzweig H., Doyle K., Lessov N.S., Simon R.P., and Stenzel-Poore M.P. Neuroprotection by osteopontin in stroke. J. Cereb. Blood Flow Metab. 25 (2005) 217-225
40. Mizuno Y., Saitoh T., and Sone N. Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. Biochem. Biophys. Res. Commun. 143 (1987) 294-299
41. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., and Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180 (1994) 147-150
42. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., and Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165 (1994) 208-210
43. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., and Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211 (1996) 13-16
44. Murry C.E., Giachelli C.M., Schwartz S.M., and Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am. J. Pathol. 145 (1994) 1450-1462
45. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36 (1985) 2503-2508
46. O'Regan A.W., Nau G.J., Chupp G.L., and Berman J.S. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks [in process citation]. Immunol. Today 21 (2000) 475-478
47. Ophascharoensuk V., Giachelli C.M., Gordon K., Hughes J., Pichler R., Brown P., Liaw L., Schmidt R., Shankland S.J., Alpers C.E., Couser W.G., and Johnson R.J. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 56 (1999) 571-580
48. Ramsay R.R., and Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261 (1986) 7585-7587
49. Rollo E.E., Laskin D.L., and Denhardt D.T. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J. Leukocyte Biol. 60 (1996) 397-404
50. Sakata M., Tsuruha J.I., Masuko-Hongo K., Nakamura H., Matsui T., Sudo A., Nishioka K., and Kato T. Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J. Rheumatol. 28 (2001) 1492-1495
51. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54 (1990) 823-827
52. Scott J.A., Weir M.L., Wilson S.M., Xuan J.W., Chambers A.F., and McCormack D.G. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am. J. Physiol. 275 (1998) H2258-H2265
53. Shin S.L., Cha J.H., Chun M.H., Chung J.W., and Lee M.Y. Expression of osteopontin mRNA in the adult rat brain. Neurosci. Lett. 273 (1999) 73-76
54. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36 (1994) 348-355
55. Smith L., De Salvia M., Jenner P., and Marsden C.D. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov. Disord. 11 (1996) 125-135
56. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., and Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251 (1998) 205-208
57. Tajouri L., Mellick A.S., Tourtellotte A., Nagra R.M., and Griffiths L.R. An examination of MS candidate genes identified as differentially regulated in multiple sclerosis plaque tissue, using absolute and comparative real-time Q-PCR analysis. Brain Res. Brain Res. Protoc. 15 (2005) 79-91
58. Takahashi F., Takahashi K., Shimizu K., Cui R., Tada N., Takahashi H., Soma S., Yoshioka M., and Fukuchi Y. Osteopontin is strongly expressed by alveolar macrophages in the lungs of acute respiratory distress syndrome. Lung 182 (2004) 173-185
59. Vila M., Jackson-Lewis V., Guegan C., Wu D.C., Teismann P., Choi D.K., Tieu K., and Przedborski S. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14 (2001) 483-489
60. Wang X., Louden C., Yue T.L., Ellison J.A., Barone F.C., Solleveld H.A., and Feuerstein G.Z. Delayed expression of osteopontin after focal stroke in the rat. J. Neurosci. 18 (1998) 2075-2083
61. Weber G.F., and Cantor H. The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev. 7 (1996) 241-248
62. Weber G.F., Adler G., and Ashkar S. Osteopontin in oxidative stress responses. In: Ruffolo R.R., Feuerstein G.Z., Hunter A.J., Poste G., and Metcalf B.W. (Eds). Inflammatory Cells and Mediators in CNS Diseases (1999), Harwood Academic Publishers, Amsterdam 97-112
63. Weber G.F., Zawaideh S., Hikita S., Kumar V.A., Cantor H., and Ashkar S. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J. Leukocyte Biol. 72 (2002) 752-761
64. Zhu B., Suzuki K., Goldberg H.A., Rittling S.R., Denhardt D.T., McCulloch C.A., and Sodek J. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J. Cell. Physiol. 198 (2004) 155-167